Last edition
News about "Pierre Fabre Pharmaceuticals"
US FDA Accepts Tabelecleucel BLA Resubmission for EBV-PTLD
The US FDA has accepted Pierre Fabre’s tabelecleucel BLA resubmission for EBV-positive PTLD, with a target decision date of March 31, 2027.
Pierre Fabre Pharmaceuticals | 15/10/2026 | By News Bureau
Pierre Fabre Resubmits Tabelecleucel BLA to FDA
Pierre Fabre Pharmaceuticals resubmits tabelecleucel BLA for treatment of Epstein-Barr virus positive -post-transplant lymphoproliferative disease to the FDA.
Pierre Fabre Pharmaceuticals | 03/10/2026 | By News Bureau
Pierre Fabre Pharmaceuticals Reports FDA Update on Tabelecleucel BLA
Pierre Fabre Pharmaceuticals aligns with US Food and Drug Administration (FDA) on BLA resubmission path for tabelecleucel, an allogeneic T-cell therapy for Epstein-Barr virus positive post-transplant lymphoproliferative disease.
Pierre Fabre Pharmaceuticals | 08/05/2026 | By News Bureau | 125
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy